[Treatment of the patient with ideal LDL cholesterol].
Coronary heart disease (CHD) is the leading cause of death worldwide. Low-density lipoprotein-cholesterol (LDL-C) reduction is the corner-stone in both primary and secondary cardiovascular prevention. Use of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors (statins) has proved to reduce LDL-C levels and major coronary event risks. The benefit on cardiovascular risk reduction is greater as LDL-C lowering is greater. Cardiovascular risk remains unacceptably high, even in patients with on-target LDL-C. This paper presents a review of alternatives for both approach and therapy in patients with on-target LDL-C.
Mendoza Pérez
Enrique
E
Departamento de Endocrinología del Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, 14080 México, D.F. emendozap@yahoo.com.mx
D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides
Tratamiento del paciente con colesterol de LDL ideal.